Having trouble accessing articles? Reset your cache.

Janssen pays $750M for XBiotech's dermatology candidate after positive Phase II data

After searching for a new candidate to add to its immuno-dermatology pipeline, Janssen Biotech Inc. will spend $750 up front to acquire bermekimab, a clinical anti-IL-1α antibody, from XBiotech Inc. The mAb is first being developed in atopic dermatitis and hidradenitis suppurativa.

The sale sent shares of XBiotech Inc. (NASDAQ:XBIT) up $8.38 (75%) to

Read the full 530 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers